A Phase I Study of LX-039 Tablets
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer
Interventions: DRUG: LX-039 tablets
Sponsor: Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.